• Molly Fitzpatrick, H Richard Alexander, Seema P Deshpande, Douglas G Martz, Brian McCormick, and Alina M Grigore.
• Division of Cardiothoracic Anesthesiology, University of Maryland School of Medicine, Baltimore, MD.
• J. Cardiothorac. Vasc. Anesth.. 2014 Jun 1;28(3):647-51.

ObjectivesDiffuse isolated liver metastases are the dominant mode of tumor progression in a number of cancers and present a major treatment challenge for oncologists. An experimental treatment, percutaneous hepatic perfusion (PHP), utilizes partial venovenous cardiopulmonary bypass to allow administration of high-dose chemotherapy directly and solely to the liver with filtration of chemotherapeutic agents from the blood prior to its return to the systemic circulation, thereby minimizing toxic systemic effects. The following case series describes the management of 5 patients with metastatic melanoma undergoing serial PHPs.DesignA single-center experience from a national multi-center random-assignment trial comparing PHP to best alternative care (BAC) in patients with diffuse melanoma liver metastases.SettingA tertiary care hospital.ParticipantsFive patients with metastatic melanoma to the liver.InterventionFive patients underwent a total of fifteen PHPs using a venovenous bypass circuit with hemofiltration, receiving hepatic intra-arterial melphalan, 3 mg/kg of ideal body weight, for 30 minutes with a total of 60 minutes of hemofiltration.Measurements And Main ResultsFive patients tolerated the procedure well with transient hemodynamic and metabolic changes.ConclusionsIn patients with diffuse isolated liver metastases, PHP is a safe and well-tolerated procedure that can be performed more than once and is associated with marked anti-tumor activity in some patients.Copyright © 2014 Elsevier Inc. All rights reserved.

29 keywords...

hide…